Chromosome 14q32.2 Imprinted Region Disruption as an Alternative Molecular Diagnosis of Silver-Russell Syndrome

Imagem de Miniatura
Arquivos
art_GEOFFRON_Chromosome_14q322_Imprinted_Region_Disruption_as_an_Alternative_2018.PDF (954.39 KB)
Citações na Scopus
39
Tipo de produção
article
Data de publicação
2018
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ENDOCRINE SOC
Autores
GEOFFRON, Sophie
HABIB, Walid Abi
CHANTOT-BASTARAUD, Sandra
DUBERN, Beatrice
STEUNOU, Virginie
AZZI, Salah
AFENJAR, Alexandra
BUSA, Tiffanny
CHALOUHI, Christel
Citação
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, v.103, n.7, p.2436-2446, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Context: Silver-Russell syndrome (SRS) (mainly secondary to 11p15 molecular disruption) and Temple syndrome (TS) (secondary to 14q32.2 molecular disruption) are imprinting disorders with phenotypic (prenatal and postnatal growth retardation, early feeding difficulties) and molecular overlap. Objective: To describe the clinical overlap between SRS and TS and extensively study the molecular aspects of TS. Patients: We retrospectively collected data on 28 patients with disruption of the 14q32.2 imprinted region, identified in our center, and performed extensive molecular analysis. Results: Seventeen (60.7%) patients showed loss of methylation of the MEG3/DLK1 intergenic differentially methylated region by epimutation. Eight (28.6%) patients had maternal uniparental disomy of chromosome 14 and three (10.7%) had a paternal deletion in 14q32.2. Most patients (72.7%) had a Netchine-Harbison SRS clinical scoring system $ 4/6, and consistent with a clinical diagnosis of SRS. The mean age at puberty onset was 7.2 years in girls and 9.6 years in boys; 37.5% had premature pubarche. The body mass index of all patients increased before pubarche and/or the onset of puberty. Multilocus analysis identified multiple methylation defects in 58.8% of patients. We identified four potentially damaging genetic variants in genes encoding proteins involved in the establishment or maintenance of DNA methylation. Conclusions: Most patients with 14q32.2 disruption fulfill the criteria for a clinical diagnosis of SRS. These clinical data suggest similar management of patients with TS and SRS, with special attention to their young age at the onset of puberty and early increase of body mass index.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/29605
Referências
  1. Azzi S, 2015, J MED GENET, V52, P446, DOI 10.1136/jmedgenet-2014-102979
  2. Azzi S, 2015, J MED GENET, V52, P53, DOI 10.1136/jmedgenet-2014-102732
  3. BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564
  4. Bena F, 2010, HUM MOL GENET, V19, P1967, DOI 10.1093/hmg/ddq075
  5. Clayton PE, 2007, J CLIN ENDOCR METAB, V92, P804, DOI 10.1210/jc.2006-2017
  6. Cleaton MAM, 2016, NAT GENET, V48, P1473, DOI 10.1038/ng.3699
  7. Dauber A, 2017, J CLIN ENDOCR METAB, V102, P1557, DOI 10.1210/jc.2016-3677
  8. DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0
  9. Gicquel C, 2005, NAT GENET, V37, P1003, DOI 10.1038/ng1629
  10. Ibanez L, 1999, J CLIN ENDOCR METAB, V84, P4739, DOI 10.1210/jc.84.12.4739
  11. Ioannides Y, 2014, J MED GENET, V51, P495, DOI 10.1136/jmedgenet-2014-102396
  12. Kagami M, 2017, GENET MED, V19, P1356, DOI 10.1038/gim.2017.53
  13. Kagami M, 2015, EUR J HUM GENET, V23, P1062, DOI 10.1038/ejhg.2014.234
  14. KOTZOT D, 1995, HUM MOL GENET, V4, P583, DOI 10.1093/hmg/4.4.583
  15. Lu Pei-ying, 2015, Zhejiang Da Xue Xue Bao Yi Xue Ban, V44, P335
  16. Mackay Deborah J. G., 2015, BioMolecular Concepts, V6, P47, DOI 10.1515/bmc-2014-0037
  17. Meister B, 2013, J NEUROENDOCRINOL, V25, P617, DOI 10.1111/jne.12029
  18. Moon YS, 2002, MOL CELL BIOL, V22, P5585, DOI 10.1128/MCB.22.15.5585-5592.2002
  19. Mosbah H, 2017, SURG OBES RELAT DIS, V13, P1248, DOI 10.1016/j.soard.2017.01.044
  20. Netchine I, 2007, J CLIN ENDOCR METAB, V92, P3148, DOI 10.1210/jc.2007-0354
  21. Olek A, 1997, NAT GENET, V17, P275, DOI 10.1038/ng1197-275
  22. Persson-Augner D, 2014, NEUROENDOCRINOLOGY, V100, P209, DOI 10.1159/000369069
  23. Poole RL, 2013, AM J MED GENET A, V161, P2174, DOI 10.1002/ajmg.a.36049
  24. Puertas-Avendano RA, 2011, J NEUROENDOCRINOL, V23, P849, DOI 10.1111/j.1365-2826.2011.02189.x
  25. Rosenfield RL, 2009, PEDIATRICS, V123, P84, DOI 10.1542/peds.2008-0146
  26. RUSSELL A, 1954, P ROY SOC MED, V47, P1040
  27. Schonherr N, 2006, EUR J MED GENET, V49, P414, DOI 10.1016/j.ejmg.2006.03.001
  28. Sempe A A, 1979, AUXOLOGIE METHODE SE
  29. Severi G, 2016, AM J MED GENET A, V170, P162, DOI 10.1002/ajmg.a.37346
  30. SILVER HK, 1953, PEDIATRICS, V12, P368
  31. SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L
  32. Smeets CCJ, 2016, J CLIN ENDOCR METAB, V101, P2105, DOI 10.1210/jc.2015-4273
  33. Takada S, 2002, HUM MOL GENET, V11, P77, DOI 10.1093/hmg/11.1.77
  34. Takenouchi T, 2015, CONGENIT ANOM, V55, P167, DOI 10.1111/cga.12105
  35. TEMPLE IK, 1991, J MED GENET, V28, P511, DOI 10.1136/jmg.28.8.511
  36. van der Steen M, 2016, J CLIN ENDOCR METAB, V101, P2005, DOI 10.1210/jc.2016-1317
  37. Verkauskiene R, 2013, HORM RES PAEDIAT, V80, P69, DOI 10.1159/000353759
  38. Wakeling EL, 2010, J MED GENET, V47, P760, DOI 10.1136/jmg.2010.079111
  39. Wakeling EL, 2017, NAT REV ENDOCRINOL, V13, P105, DOI 10.1038/nrendo.2016.138
  40. Williams RM, 2012, ARCH DIS CHILD, V97, P250, DOI 10.1136/archdischild-2011-300011

Coleções
Artigos e Materiais de Revistas Científicas - FM/Outros